ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1.4 | 3.3 | 2.7 |
| Total income | 1.4 | 3.3 | 2.8 |
| Profit before exceptional items & tax | 0.1 | 0.7 | -0.2 |
| Profit before tax | 0.1 | 0.7 | -0.2 |
| Net profit | 0.1 | 0.7 | -0.2 |
| Operating margin | 7.1% | 21.2% | -7.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -85.70% |
|---|---|
| Revenue, year on year | -48.10% |
BSE results filing, NSE: NORRIS. Figures extracted from the filing.
Norris Medicines Ltd: key numbers
- Share price
- ₹14.25
- Market cap
- ₹14.25 Cr
- Revenue (annual)
- ₹8.13 Cr
- Net profit (annual)
- ₹-0.28 Cr
- P/E (TTM)
- -38.8×Sector 43.8×
- Promoter holding
- 34.01%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Norris Medicines Ltd
All →Norris Medicines Board Meeting Date
Norris Medicines Limited intimated a prior board meeting on 14 Nov 2026 to consider unaudited standalone quarterly results for September 2026. Trading window closed from 01 Oct to 16 Nov 2026.
Norris Medicines Other Announcement
Norris Medicines Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI regulations.
Norris Medicines Annual General Meeting
Norris Medicines Limited held its 35th Annual General Meeting on September 29, 2026, where members transacted various ordinary and special business items.
Norris Medicines Annual Report
Norris Medicines Limited has filed its 35th Annual Report for the financial year 2025-26, including the notice of its upcoming Annual General Meeting.
Norris Medicines Annual General Meeting
Norris Medicines approved the Directors' Report, Annual Report, and convening of the 35th Annual General Meeting for September 29, 2026.
Norris Medicines Q1 FY27 Results: Net Loss of ₹0.4 Cr, Loss Widens
Norris Medicines Ltd reported revenue from operations of ₹0.9 Cr (-40.0% YoY) and a net loss of ₹0.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.4 Cr